Coronavirus

Aptevo Therapeutics Provides Pipeline Update

Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now…

2 years ago

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical…

2 years ago

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new…

2 years ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sales Grew at an Average Rate of 14% Per Quarter During the YearNEW YORK, NY / ACCESSWIRE / April 1,…

2 years ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Medical oncologist brings over 25 years of industry experience to lead Clinical Development StrategyBOSTON, March 28, 2024 (GLOBE NEWSWIRE) --…

2 years ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza…

2 years ago

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpointsExpects two more Phase 3…

2 years ago

Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024

LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser…

2 years ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced…

2 years ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) --…

2 years ago